PCI Clinical Services Brochure

The first-of-its-kind centre will offer biopharma clients convenience and efficiencies in the rapidly expanding Northeast

Targeted protein degraders (TPDs), including PROTACs and molecular glues, represent a transformative therapeutic approach but face significant challenges in oral delivery due to their size, polarity, and poor solubility. Enhancing bioavailability is therefore critical to unlocking their full clinical potential. In this presentation, David O’Connell, Director of Scientific Affairs at PCI Pharma Services, will explore the latest bioavailability enhancement strategies for TPDs, from hot melt extrusion and nanomilling to advanced spray drying and nanotechnology. He will also highlight PCI’s strategic partnerships with leading solubility experts, enabling integrated, end-to-end solutions that accelerate development and improve outcomes for complex molecules.

With over fifty years of packaging expertise and in excess of 50 successful product launches per year, PCI is a trusted leader and industry expert in the commercialization of new medicines.

Through the acquisition of Penn Pharma, PCI has significant experience in providing integrated drug development, clinical trial supply and commercial manufacturing of solid dose,liquid and semi-solid potent products to high standards of safety and quality.